logo
Plus   Neg
Share
Email

AstraZeneca: Calquence Trial In Chronic Lymphocytic Leukaemia Met Primary Goal

British drug major AstraZeneca Plc (AZN.L,AZN) announced Tuesday that the Phase III ASCEND trial of Calquence (acalabrutinib) in previously-treated patients with chronic lymphocytic leukaemia or CLL met primary endpoint.

The positive results showed a statistically-significant and clinically-meaningful improvement in progression-free survival with Calquence monotherapy compared to a combination regimen of rituximab plus physician's choice of idelalisib or bendamustine.

The safety and tolerability of Calquence was consistent with the known profile, the company noted.

According to the company, Calquence is the first Bruton tyrosine kinase or BTK inhibitor to show benefit in a Phase III trial as a monotherapy compared to current standard-of-care combinations used in relapsed or refractory CLL.

ASCEND is the first of two Phase III CLL trials expected to read out in 2019. The second is ELEVATE-TN in treatment-naïve, front-line CLL.

Calquence is currently approved for the treatment of adults with relapsed or refractory mantle cell lymphoma or MCL in the US, Brazil, the UAE, and Qatar. It is being developed for the treatment of CLL and other blood cancers.

AstraZeneca and its haematology research and development arm Acerta Pharma are currently evaluating Calquence in 26 clinical trials.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
AMC Entertainment Holdings, Inc., the world's largest theatre chain, said it has substantial doubt in its ability to continue its business as theaters across the world remain closed for months now following coronavirus or Covid-19 pandemic. In a regulatory filing, the company said it is "generating effectively no revenue", and that additional capital, if needed, may not be available. Apple is tracking iPhones that were stolen from its retail stores in recent days during the civil unrest, according to reports citing a warning message popping up on the stolen iPhones. Four current and former senior executives from two major broiler chicken producers, including Pilgrim's Pride CEO Jayson Penn, have been indicted for price fixing.
Follow RTT